{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:00:11Z","timestamp":1758981611450},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T00:00:00Z","timestamp":1370390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s11096-013-9780-1","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T07:55:19Z","timestamp":1370332519000},"page":"513-519","source":"Crossref","is-referenced-by-count":3,"title":["Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?"],"prefix":"10.1007","volume":"35","author":[{"given":"Vanessa","family":"Hegele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"W\u00fcst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Ehrenbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza Raquel","family":"Grazziotin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Prohonoski","family":"Caregnato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciane Pereira","family":"Lindenmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"key":"9780_CR1","volume-title":"Guidelines for the diagnosis and management of lymphoma","author":"Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party","year":"2005","unstructured":"Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the diagnosis and management of lymphoma. Sydney: The Cancer Council Australia and Australian Cancer Network; 2005."},{"issue":"3","key":"9780_CR2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","volume":"8","author":"AD Zelenetz","year":"2010","unstructured":"Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN Clinical Practice Guidelines in oncology: non-Hodgkin\u2019s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288\u2013334.","journal-title":"J Natl Compr Canc Netw"},{"key":"9780_CR3","unstructured":"Rituximabe no tratamento do linfoma difuso de grandes c\u00e9lulas B [Rituximab in the treatment of diffuse large B cell lymphoma]. Brazilian Bulletin on Health Technology Assessment (BRATS) [serial on the Internet]. 2009;4(10); Available from: http:\/\/200.214.130.94\/rebrats\/brats.php ."},{"issue":"2","key":"9780_CR4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2006.10.005","volume":"33","author":"MC Cheung","year":"2007","unstructured":"Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev. 2007;33(2):161\u201376.","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"9780_CR5","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9780_CR6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417\u201323.","journal-title":"Blood"},{"issue":"4","key":"9780_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"key":"9780_CR8","unstructured":"Freedman A, Friedberg J. Initial treatment of follicular lymphoma. 2013 [cited 2013 03\/31\/2013]; Available from: http:\/\/www.uptodate.com ."},{"issue":"12","key":"9780_CR9","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00a0\u00d7\u00a04 schedule. Blood. 2004;103(12):4416\u201323.","journal-title":"Blood"},{"key":"9780_CR10","unstructured":"Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin\u2019s lymphoma: systematic review and economic evaluation. Health Technol Assess. 2004;8(37):iii, ix\u2013xi, 1\u201382."},{"issue":"10","key":"9780_CR11","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295\u2013301.","journal-title":"Blood"},{"issue":"6","key":"9780_CR12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med. 2008;359(6):613\u201326.","journal-title":"N Engl J Med"},{"key":"9780_CR13","unstructured":"MabThera\u00ae (rituximab). F. Hoffmann-La Roche; 2013 [cited 2013 03\/31\/2013]; Available from: http:\/\/www.dialogoroche.com.br\/content\/dam\/dialogo\/pt_br\/Bulas\/M\/MabThera\/mabthera-profissional-20120119.pdf ."},{"issue":"17","key":"9780_CR14","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853\u20138.","journal-title":"J Clin Oncol"},{"key":"9780_CR15","volume-title":"Consenso Brasileiro de Aten\u00e7\u00e3o Farmac\u00eautica [Brazilian Consensus on Pharmaceutical Care]","author":"A Ivama","year":"2002","unstructured":"Ivama A, Noblat L, de Castro M, de Oliveira N, Jaramillo N, Rech N. Consenso Brasileiro de Aten\u00e7\u00e3o Farmac\u00eautica [Brazilian Consensus on Pharmaceutical Care]. 1st ed. Bras\u00edlia: Organiza\u00e7\u00e3o Pan-Americana da Sa\u00fade; 2002.","edition":"1"},{"issue":"2","key":"9780_CR16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11096-007-9157-4","volume":"30","author":"U Jaehde","year":"2008","unstructured":"Jaehde U, Liekweg A, Simons S, Westfeld M. Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci. 2008;30(2):161\u20138.","journal-title":"Pharm World Sci"},{"issue":"3","key":"9780_CR17","first-page":"533","volume":"47","author":"CD Hepler","year":"1990","unstructured":"Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533\u201343.","journal-title":"Am J Hosp Pharm"},{"issue":"1","key":"9780_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/02841860903150502","volume":"49","author":"G Gao","year":"2010","unstructured":"Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin\u2019s lymphoma. Acta Oncol. 2010;49(1):3\u201312.","journal-title":"Acta Oncol"},{"key":"9780_CR19","doi-asserted-by":"crossref","unstructured":"Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma. Cochrane Database Syst Rev. 2007;(4). doi: 10.1002\/14651858.CD003805.pub2 .","DOI":"10.1002\/14651858.CD003805.pub2"},{"issue":"11","key":"9780_CR20","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.22666","volume":"109","author":"PI Rafailidis","year":"2007","unstructured":"Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer. 2007;109(11):2182\u20139.","journal-title":"Cancer"},{"key":"9780_CR21","doi-asserted-by":"crossref","unstructured":"Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev. 2009;(2). doi: 10.1002\/14651858.CD006552.pub2 .","DOI":"10.1002\/14651858.CD006552.pub2"},{"key":"9780_CR22","doi-asserted-by":"crossref","unstructured":"Mart\u00ed-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin\u2019s lymphoma. Cochrane Database Syst Rev. 2009;(3):CD005419.","DOI":"10.1002\/14651858.CD005419.pub2"},{"issue":"12","key":"9780_CR23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"18","key":"9780_CR24","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9780_CR25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","volume":"106","author":"LD Kaplan","year":"2005","unstructured":"Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538\u201343.","journal-title":"Blood"},{"issue":"2","key":"9780_CR26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","journal-title":"Lancet Oncol"},{"key":"9780_CR27","unstructured":"CHOP-R. Ontario: Juravinski Cancer Centre; 2008 [cited 2013 03\/12\/2013]; Available from: http:\/\/www.jcc.hhsc.ca\/workfiles\/PHARMACY\/HE-CHOP-R.pdf ."},{"key":"9780_CR28","unstructured":"Non-Hodgkin\u2019s Lymphomas. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2013 ed: National Comprehensive Cancer Network; 2012."},{"key":"9780_CR29","unstructured":"Guidance on the administration of rituximab infusions. London: The North London Cancer Network; 2009 [cited 2013 03\/31\/2013]; Available from: http:\/\/www.nlcn.nhs.uk\/BChemoGui ."},{"key":"9780_CR30","unstructured":"Guidelines for the management of tumour lysis syndrome. London: The North London Cancer Network; 2010 [cited 2013 03\/31\/2013]; Available from: http:\/\/www.nlcn.nhs.uk\/BChemoGui ."},{"issue":"1","key":"9780_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/107815529500100101","volume":"1","author":"L Broadfield","year":"1995","unstructured":"Broadfield L. Pharmaceutical care in oncology pharmacy practice: a method for using outcome indicators. J Oncol Pharm Pract. 1995;1(1):9\u201314.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"9780_CR32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1130-6343(07)75379-5","volume":"31","author":"E Cavero Rodrigo","year":"2007","unstructured":"Cavero Rodrigo E, Climente Mart\u00ed M, Navarro Fontestad MC, Jim\u00e9nez Torres NV. Quality assessment of two pharmaceutical care models for onco-haematological patients. Farm Hosp. 2007;31(4):231\u20137.","journal-title":"Farm Hosp"},{"issue":"1","key":"9780_CR33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/107815529900500104","volume":"5","author":"S Wong","year":"1999","unstructured":"Wong S, Gray E. Clinical pharmacy services in oncology clinics. J Oncol Pharm Pract. 1999;5(1):49\u201354.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"9780_CR34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2478\/v10019-010-0040-x","volume":"44","author":"L Knez","year":"2010","unstructured":"Knez L, Laaksonen R, Duggan C. Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol. 2010;44(4):249\u201356.","journal-title":"Radiol Oncol"},{"issue":"2","key":"9780_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1191\/1078155205jp156oa","volume":"11","author":"A Serrano-Fabi\u00e1","year":"2005","unstructured":"Serrano-Fabi\u00e1 A, Cavero Rodrigo E, Albert Mar\u00ed A, Almenar Cubells D, Jim\u00e9nez Torres NV. Pharmaceutical validation as a process of improving the quality of antineoplastic treatment. J Oncol Pharm Pract. 2005;11(2):45\u201350.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"9780_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1078155209340482","volume":"16","author":"A Serrano-Fabi\u00e1","year":"2010","unstructured":"Serrano-Fabi\u00e1 A, Albert-Mar\u00ed A, Almenar-Cubells D, Jim\u00e9nez-Torres NV. Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy. J Oncol Pharm Pract. 2010;16(2):105\u201312.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"9780_CR37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1078155206070412","volume":"12","author":"E Bremberg","year":"2006","unstructured":"Bremberg E, Hising C, Nylen U, Ehrsson H, Eksborg S. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract. 2006;12(2):75\u201381.","journal-title":"J Oncol Pharm Pract"},{"issue":"19","key":"9780_CR38","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187\u2013205.","journal-title":"J Clin Oncol"},{"key":"9780_CR39","first-page":"452","volume-title":"QuapoS 4: quality standard for the oncology pharmacy service with commentary","author":"M Eisenach","year":"2009","unstructured":"Eisenach M. Pharmaceutical counseling. In: Pharmacy GSoO, editor. QuapoS 4: quality standard for the oncology pharmacy service with commentary. Hamburg: European Society of Oncology Pharmacy (ESOP); 2009. p. 452."},{"key":"9780_CR40","volume-title":"Farm\u00e1cia Cl\u00ednica e Aten\u00e7\u00e3o Farmac\u00eautica [Clinical pharmacy and pharmaceutical care]","author":"M Castro","year":"2008","unstructured":"Castro M, Fuchs F, Ferreira M. Reflex\u00e3o sobre a pr\u00e1tica e o ensino do seguimento farmacoterap\u00eautico de pacientes [Reflection on the practice and teaching of patients pharmacotherapeutic follow-up]. In: Storpirtis S, Mori A, Yochiy A, Ribeiro E, Porta V, editors. Farm\u00e1cia Cl\u00ednica e Aten\u00e7\u00e3o Farmac\u00eautica [Clinical pharmacy and pharmaceutical care]. Rio de Janeiro: Guanabara Koogan; 2008."},{"key":"9780_CR41","volume-title":"Farm\u00e1cia Cl\u00ednica e Aten\u00e7\u00e3o Farmac\u00eautica [Clinical pharmacy and pharmaceutical care]","author":"M Witzel","year":"2008","unstructured":"Witzel M. Aspectos conceituais e filos\u00f3ficos da Assist\u00eancia Farmac\u00eautica, Farm\u00e1cia Cl\u00ednica e Aten\u00e7\u00e3o Farmac\u00eautica [Conceptual and philosophical aspects of pharmaceutical services, clinical pharmacy and pharmaceutical care]. In: Storpirtis S, Mori A, Yochiy A, Ribeiro E, Porta V, editors. Farm\u00e1cia Cl\u00ednica e Aten\u00e7\u00e3o Farmac\u00eautica [Clinical pharmacy and pharmaceutical care]. Rio de Janeiro: Guanabara Koogan; 2008."},{"issue":"7","key":"9780_CR42","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00520-010-0927-5","volume":"19","author":"S Simons","year":"2011","unstructured":"Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer. 2011;19(7):1009\u201318.","journal-title":"Support Care Cancer"},{"issue":"4","key":"9780_CR43","first-page":"375","volume":"55","author":"R Moreira","year":"2009","unstructured":"Moreira R. Suggesting pharmacotherapeutical follow-up in chronic myeloid leukemia: a methodological approach model. Braz J Oncol. 2009;55(4):375\u20138.","journal-title":"Braz J Oncol"},{"issue":"1","key":"9780_CR44","first-page":"1","volume":"3","author":"C Omoti","year":"2005","unstructured":"Omoti C, Agada L. Compliance with chemotherapy in adult leukemia patients in Benin City, Nigeria. Seguimiento Farmacoterap\u00e9utico. 2005;3(1):1\u20139.","journal-title":"Seguimiento Farmacoterap\u00e9utico"},{"issue":"5","key":"9780_CR45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626\u201330.","journal-title":"Leuk Res"},{"issue":"4","key":"9780_CR46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2354.2010.01212.x","volume":"20","author":"V Denois","year":"2011","unstructured":"Denois V, Nourissat A, Jacquin J, Guastalla J, Chauvin F. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care. 2011;20(4):520\u20137.","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"9780_CR47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2354.2010.01198.x","volume":"19","author":"C Oakley","year":"2010","unstructured":"Oakley C. Developing an intervention for cancer patients prescribed oral chemotherapy: a generic patient diary. Eur J Cancer Care. 2010;19(1):21\u20138.","journal-title":"Eur J Cancer Care"},{"issue":"7522","key":"9780_CR48","first-page":"399","volume":"281","author":"S Williamson","year":"2008","unstructured":"Williamson S. Management of oral anticancer therapies. Pharm J. 2008;281(7522):399\u2013402.","journal-title":"Pharm J"},{"issue":"14","key":"9780_CR49","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/ajhp\/61.14.1466","volume":"61","author":"AJ Forster","year":"2004","unstructured":"Forster AJ, Halil RB, Tierney MG. Pharmacist surveillance of adverse drug events. Am J Health Syst Pharm. 2004;61(14):1466\u201372.","journal-title":"Am J Health Syst Pharm"},{"issue":"18","key":"9780_CR50","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ajhp\/59.18.1742","volume":"59","author":"AG Winterstein","year":"2002","unstructured":"Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital\u2019s database of adverse drug reaction reports. Am J Health Syst Pharm. 2002;59(18):1742\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"9780_CR51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/107815520000600205","volume":"6","author":"J Roscoe","year":"2000","unstructured":"Roscoe J, Goransson E, Slancar M, Smith J, Taylor S, Tyson S. A multidisciplinary approach to ensure safety in the prescribing and administration of chemotherapy. J Oncol Pharm Pract. 2000;6(2):60\u20133.","journal-title":"J Oncol Pharm Pract"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-013-9780-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9780-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T15:10:50Z","timestamp":1563117050000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-013-9780-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,5]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9780"],"URL":"https:\/\/doi.org\/10.1007\/s11096-013-9780-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,5]]}}}